# Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

> **NCT03400800** · PHASE3 · COMPLETED · sponsor: **The Medicines Company** · enrollment: 1617 (actual)

## Conditions studied

- ASCVD
- Risk Factor, Cardiovascular
- Elevated Cholesterol

## Interventions

- **DRUG:** Inclisiran Sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03400800
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-08-27
- **Target enrollment:** 1617 (ACTUAL)
- **Last updated:** 2020-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03400800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03400800, "Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03400800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*